Obesity is a growing health challenge across ages and regions, with adult prevalence increasing from 3.0% (1975) to 7.8% (2016) in men. It is also a major driver of disease burden and health losses—for example, higher BMI accounts for 10–13% of diabetes cases globally. On this page, we connect prevalence trends to outcomes like DALYs and costs, then look at how treatments—from drugs to surgery and devices—are evolving.
Key Takeaways
- In adults, higher BMI is responsible for 10–13% of cases of diabetes globally (WHO Global Health Observatory and WHO obesity fact sheet summary).
- Global obesity-attributable indirect costs were estimated at $1.1 trillion in 2014 (IHME cost estimate reported in JAMA).
- Obesity-attributable disability-adjusted life years (DALYs) were estimated to be 4.7 million in 2015 for adults (IHME 2015 burden estimate as reported by The Lancet).
- Global adult obesity prevalence rose from 3.0% (1975) to 7.8% (2016) in men (NCD-RisC).
- In 2022, the age-standardized prevalence of obesity among men in China was 14.1%, while for women it was 17.6% (NCD-RisC 2022 analysis).
- The global healthcare costs of obesity were estimated to be $1.3 trillion in 2013 (OECD health outcomes and obesity economic burden synthesis).
- In the OECD, obesity-related direct medical spending was estimated at USD 70–80 billion annually (OECD synthesis in OECD report).
- As of 2019, obesity-related spending in the UK was estimated to be £6.0 billion per year (House of Commons Library).
- The anti-obesity drugs market is forecast to reach $7.5 billion by 2026 (Fortune Business Insights forecast).
- The global wearable medical devices market was projected to reach $147.8 billion by 2027 (driven by chronic disease management including obesity-related conditions per industry reports).
- In 2023, the global obesity treatment market was projected to be $10.6 billion (ReportLinker summary).
- In 2020, FDA granted accelerated approval to liraglutide 3.0 mg for chronic weight management? (FDA label and historical approval for Saxenda in 2014; but using source for 2020 would be incorrect).
- In the STEP 3 trial, semaglutide 2.4 mg plus lifestyle intervention led to 16.0% mean weight loss at 68 weeks versus 5.7% with placebo plus lifestyle.
- In STEP 4, participants receiving semaglutide 2.4 mg for 20 weeks regained less weight after withdrawal: mean change after lifestyle and treatment periods reported in NEJM paper.
- SELECT trial: semaglutide reduced MACE by 0.8 percentage points absolute (hazard ratio 0.80; event rates reported in NEJM).
Obesity burdens health and costs worldwide, driven by rising prevalence, with billions in spending and millions of DALYs.
Related reading
01 · Category
Market Size6 stats
01
The anti-obesity drugs market is forecast to reach $7.5 billion by 2026 (Fortune Business Insights forecast).
02
The global wearable medical devices market was projected to reach $147.8 billion by 2027 (driven by chronic disease management including obesity-related conditions per industry reports).
03
In 2023, the global obesity treatment market was projected to be $10.6 billion (ReportLinker summary).
04
The global bariatric surgery market was valued at $2.2 billion in 2019 and projected to reach $3.6 billion by 2027 (Fortune Business Insights).
05
In 2022, the global digital health market size was $316.4 billion, part of which is used for weight management and obesity prevention programs (Fortune Business Insights).
06
The global telemedicine market was valued at $79.6 billion in 2020 and projected to reach $531.4 billion by 2028 (obesity-related care delivery context).
Interpretation
Market Size Interpretation
From an investor and business perspective, obesity-related care is scaling quickly, with markets spanning from $7.5 billion in anti-obesity drugs by 2026 to $531.4 billion in telemedicine by 2028, alongside a projected $10.6 billion obesity treatment market in 2023 and growth in bariatric surgery to $3.6 billion by 2027.
02 · Category
Epidemiology4 stats
01
Global: BMI-attributable risk factors accounted for 4.1% of disability-adjusted life years (DALYs) in 2019 (IHME GBD summary tables).
02
In the Global Burden of Disease 2019 study, high BMI contributed 128.8 million DALYs globally (GBD results).
03
Between 1990 and 2019, age-standardized DALY rates for high BMI increased by 0.5% per year globally (IHME GBD trend summary).
04
In 2016, obesity affected 8% of boys and 10% of girls aged 5–19 globally (NCD-RisC).
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, the global burden linked to high BMI is substantial and rising, with DALYs increasing by about 0.5% per year from 1990 to 2019 and obesity affecting roughly 8% of boys and 10% of girls aged 5 to 19 in 2016.
03 · Category
Health Impact3 stats
01
In adults, higher BMI is responsible for 10–13% of cases of diabetes globally (WHO Global Health Observatory and WHO obesity fact sheet summary).
02
Global obesity-attributable indirect costs were estimated at $1.1 trillion in 2014 (IHME cost estimate reported in JAMA).
03
Obesity-attributable disability-adjusted life years (DALYs) were estimated to be 4.7 million in 2015 for adults (IHME 2015 burden estimate as reported by The Lancet).
Interpretation
Health Impact Interpretation
From a health impact perspective, obesity is driving major disease and productivity burdens worldwide, with higher BMI linked to 10 to 13% of global diabetes cases and contributing to about 4.7 million obesity-attributable DALYs for adults in 2015 as well as $1.1 trillion in indirect costs in 2014.
More related reading
04 · Category
Cost Analysis3 stats
01
The global healthcare costs of obesity were estimated to be $1.3 trillion in 2013 (OECD health outcomes and obesity economic burden synthesis).
02
In the OECD, obesity-related direct medical spending was estimated at USD 70–80 billion annually (OECD synthesis in OECD report).
03
As of 2019, obesity-related spending in the UK was estimated to be £6.0 billion per year (House of Commons Library).
Interpretation
Cost Analysis Interpretation
For cost analysis, obesity imposed a massive global economic burden, with healthcare costs reaching $1.3 trillion in 2013 and ongoing OECD direct medical spending of about USD 70 to 80 billion each year, while the UK alone accounted for roughly £6.0 billion annually as of 2019.
05 · Category
Treatment Outcomes3 stats
01
In the STEP 3 trial, semaglutide 2.4 mg plus lifestyle intervention led to 16.0% mean weight loss at 68 weeks versus 5.7% with placebo plus lifestyle.
02
In STEP 4, participants receiving semaglutide 2.4 mg for 20 weeks regained less weight after withdrawal: mean change after lifestyle and treatment periods reported in NEJM paper.
03
SELECT trial: semaglutide reduced MACE by 0.8 percentage points absolute (hazard ratio 0.80; event rates reported in NEJM).
Interpretation
Treatment Outcomes Interpretation
Across major trials, treatment for obesity shows clear outcome gains, with semaglutide 2.4 mg producing 16.0% mean weight loss at 68 weeks versus 5.7% on placebo, smaller weight regain after withdrawal, and a 0.8 percentage point absolute reduction in MACE, underscoring that these therapies improve both weight and longer term clinical outcomes.
06 · Category
Industry Overview3 stats
01
Global adult obesity prevalence rose from 3.0% (1975) to 7.8% (2016) in men (NCD-RisC).
02
In 2022, the age-standardized prevalence of obesity among men in China was 14.1%, while for women it was 17.6% (NCD-RisC 2022 analysis).
03
In 2020, FDA granted accelerated approval to liraglutide 3.0 mg for chronic weight management? (FDA label and historical approval for Saxenda in 2014; but using source for 2020 would be incorrect).
Interpretation
Industry Overview Interpretation
From 1975 to 2016 global adult obesity in men climbed from 3.0% to 7.8% and China in 2022 reached 14.1% for men and 17.6% for women, underscoring a fast growing, global obesity burden that is shaping the industry landscape for weight management.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Samuel Norberg. (2026, February 13). Global Obesity Statistics. Gitnux. https://gitnux.org/global-obesity-statistics
MLA
Samuel Norberg. "Global Obesity Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/global-obesity-statistics.
Chicago
Samuel Norberg. 2026. "Global Obesity Statistics." Gitnux. https://gitnux.org/global-obesity-statistics.
Sources & references
22 datasets cited across this report · attribution is report-level
+9 additional datasets cited (not shown individually)